MK 2206

Drug Profile

MK 2206

Alternative Names: BIND 2206; BIND-2206-accurins; MK 2206 Accurin™; MK-2206; NSC-749607

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co; University of California at San Francisco
  • Developer AstraZeneca; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center
  • Class 3-ring heterocyclic compounds; Amines; Antineoplastics; Cyclobutanes
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Colorectal cancer; Endometrial cancer; Haematological malignancies; Non-small cell lung cancer; Solid tumours
  • No development reported Neuroendocrine tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 30 Jun 2017 National Cancer Institute completes a phase II trial in Endometrial cancer (Recurrent, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT01312753)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in United Kingdom (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top